Want to see XWEL full AI Analyst Report?
XWEL Stock Chart & Stats
$1.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.26 - $2.20
Previous CloseN/A
Volume31.77K
Average Volume (3M)46.47K
Market Cap
$6.81M
Enterprise Value$14.45M
Total Cash (Recent Filing)$11.78M
Total Debt (Recent Filing)$7.29M
Price to Earnings (P/E)―
Beta-0.19
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.29
Shares Outstanding9,970,883
10 Day Avg. Volume79,659
30 Day Avg. Volume46,470
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.07
Price to Sales (P/S)0.05
P/FCF Ratio-0.13
Enterprise Value/Market Cap2.12
Enterprise Value/Revenue0.51
Enterprise Value/Gross Profit1.66
Enterprise Value/Ebitda-0.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt And Asset PositionDebt reduction and asset growth provide some improvement in the company’s financial position despite its broader capital-structure stress. Lower debt can reduce future financing pressure, while a larger asset base may support strategic execution and preserve options over the next several quarters.
Gross Margin ImprovementImproving gross profitability indicates that the underlying service economics have strengthened from the 2023 trough. If maintained, this could provide a better foundation for operating leverage, although the company still needs substantially lower operating costs for the improvement to translate into sustainable earnings.
XpresTest Ownership And Sale PreparationSimplifying XpresTest’s capitalization before the planned transaction should make the subsidiary easier to transfer and reduces the risk that sale proceeds are diminished by unresolved award-related expenses. This represents a concrete strategic step toward executing the announced portfolio transaction.
Bears Say
Persistent Losses And Revenue ContractionDeep operating losses and an approximately negative 83% net margin show that the current revenue base is not covering the company’s cost structure. Sharp TTM revenue contraction further weakens scale economics, making a durable return to profitability dependent on materially improving sales and expense discipline.
Persistent Cash ConsumptionOngoing negative operating and free cash flow means the business is consuming cash rather than funding operations internally. Persistence across multiple periods increases dependence on external funding and raises dilution or refinancing risk, limiting flexibility to invest in growth while losses continue.
Negative Shareholders’ EquityNegative shareholders’ equity materially weakens the balance sheet and reduces financial flexibility. It also makes leverage measures less informative while signaling that accumulated losses have eroded the capital base, leaving the company less able to absorb further operating weakness or fund initiatives internally.
XWELL News
XWEL FAQ
What was XWELL’s price range in the past 12 months?
XWELL lowest stock price was $0.26 and its highest was $2.20 in the past 12 months.
What is XWELL’s market cap?
XWELL’s market cap is $6.81M.
When is XWELL’s upcoming earnings report date?
XWELL’s upcoming earnings report date is Nov 18, 2026 which is in 25 days.
How were XWELL’s earnings last quarter?
XWELL released its earnings results on Aug 17, 2026. The company reported -$0.264 earnings per share for the quarter.
Is XWELL overvalued?
According to Wall Street analysts XWELL’s price is currently Overvalued.
Does XWELL pay dividends?
XWELL does not currently pay dividends.
What is XWELL’s EPS estimate?
XWELL’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XWELL have?
XWELL has 9,970,883 shares outstanding.
What happened to XWELL’s price movement after its last earnings report?
XWELL reported an EPS of -$0.264 in its last earnings report. Following the earnings report the stock price went down -5.102%.
Which hedge fund is a major shareholder of XWELL?
Currently, no hedge funds are holding shares in XWEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XWELL
XWELL Inc. functions as a health and wellness services provider, primarily operating within airports. The company delivers its diverse offerings through various brands, including XpresSpa, XpresTest, Treat, and HyperPointe. Its core services feature a range of spa treatments such as massages, nail care, and skincare, further complemented by the sale of spa, travel, and general retail merchandise. Beyond relaxation services, XWELL also manages dedicated wellness centers. These facilities provide crucial health diagnostic services, encompassing COVID-19 screening and testing, rapid tests for various communicable diseases like influenza, RSV, and different flu strains (A&B), alongside seasonal flu vaccinations and other medical diagnostic procedures. To enhance accessibility for the traveling public, the company utilizes an integrated digital platform and a tailored retail selection. As of December 31, 2021, XWELL maintained a significant global presence, with 52 spa and clinic locations spanning 24 airports across the United States, the Netherlands, and the United Arab Emirates. The organization, headquartered in New York, New York, underwent a name change in October 2022, transitioning from its former identity as XpresSpa Group, Inc. to its current designation, XWELL Inc.
Technical Analysis
Medifast
―
Regis
―
MEDIROM Healthcare Technologies
―
E-Home Household Service Holdings
―
Interactive Strength Inc
―
Ownership Overview
19.64% Insiders
1.04% Mutual Funds
<0.01% Other Institutional Investors
78.81% Public Companies and
Individual Investors